COVID-19 Reinfection

COVID-19 reinfection — testing positive for SARS-CoV-2 after a prior infection — has become increasingly common since the emergence of Omicron in late 2021. Prior to Omicron, reinfection was relatively rare because immunity from original-strain infection provided strong cross-protection. Omicron's extensive mutations in the spike protein allowed it to partially evade that immunity, making reinfection dramatically more common.

Key findings from population-level surveillance:

• An Imperial College London analysis of UK Health Security Agency (UKHSA) and NHS surveillance data found that protection from a prior infection fell to about 19% against Omicron reinfection (95% CI 0–27%),^[RI2] compared with roughly 84% protection measured in the pre-Omicron era by the UKHSA-led SIREN study of healthcare workers^[RI3]
• A 2022 study in Nature Medicine (Al-Aly et al.) found that reinfected individuals — even those whose initial infections were mild — had elevated risks of adverse health outcomes compared to those infected only once
• Under CDC surveillance conventions, a positive test ≥90 days after a prior confirmed infection has generally been counted as a reinfection, though positive tests as early as 28 days after recovery can occur

Natural immunity from a COVID-19 infection provides protection, but that protection wanes over time and is variant-dependent:

• Minimum interval: Under CDC surveillance definitions, infections within about 28 days of each other have generally been treated as the same episode rather than a reinfection. Reinfection within 90 days is possible but less common
• Typical pattern: Most reinfections are documented 90 days or more after the prior infection. Protection is generally strongest in the first 3–6 months
• Variant escape: Each new subvariant (such as JN.1 and its descendants XFG and NB.1.8.1) introduces mutations that can partially evade immunity from prior Omicron infections, shortening the effective protection window
• Vaccination extends protection: Hybrid immunity — prior infection plus vaccination — provides longer-lasting and broader protection against reinfection than either alone

This is the most important finding about COVID reinfection. Research from the VA St. Louis Health Care System, led by Dr. Ziyad Al-Aly and published in Nature Medicine (2022), analyzed more than 440,000 COVID-19 patients and found:

• Reinfection was associated with increased risk of death, hospitalization, and adverse health outcomes compared to no reinfection — even when the reinfection was mild
• Risk accumulates with each infection. People with two or more infections had higher risk of Long COVID symptoms than those with one infection
• This held true across vaccinated and unvaccinated individuals, though absolute risk was lower in vaccinated people
• Organ systems affected included the lungs, heart, blood, kidneys, diabetes, gastrointestinal tract, musculoskeletal system, and neurological function

The key takeaway: a "mild" reinfection that resolves quickly does not mean zero long-term consequence. Preventing reinfection — through vaccination, good ventilation, and appropriate masking — remains worthwhile even for people who have already had COVID.^[RI1]

The same strategies that reduce initial COVID-19 risk reduce reinfection risk:

• Stay up to date on vaccinations: Updated COVID-19 vaccines targeting current circulating strains provide better protection against reinfection and severe disease. The FDA authorizes updated formulations annually to match the dominant variant
• Improve indoor air quality: SARS-CoV-2 spreads primarily through airborne transmission. HEPA air purifiers significantly reduce viral load in indoor spaces. CO₂ monitors help identify poorly ventilated rooms
• Wear a well-fitting respirator: NIOSH-approved N95 or ASTM-compliant KN95/KF94 masks in high-risk indoor settings substantially reduce exposure. Surgical masks provide less protection against aerosol inhalation
• Test when symptomatic: Confirming infection early allows access to antivirals like Paxlovid, which must be started within 5 days of symptom onset. Whether it also reduces Long COVID risk is being studied and is not established

The findings above are the most consequential on this page and also the most contested, so they deserve their limitations stated plainly rather than buried.

The Al-Aly cohort is a specific population. The Nature Medicine analysis draws on US Department of Veterans Affairs health records. That cohort is predominantly older and predominantly male, and it is a population with more baseline comorbidity than the US adult population. Its findings about relative risk may hold across groups, but the absolute risks it reports should not be read as the risks facing a healthy 30-year-old.

It is observational, not randomised. Nobody can randomise people to be reinfected. That means the comparison is between people who happened to be reinfected and people who were not, and the two groups differ in ways that also affect health outcomes — exposure, occupation, underlying illness, health-seeking behaviour. Statistical adjustment reduces this problem; it does not eliminate it, and critics of the study have focused specifically on the composition of its comparison groups.

The immunity estimates come from a different era and a different country. The 19% figure for protection against Omicron reinfection (95% CI 0–27%) is from an Imperial College analysis of UKHSA data in late 2021 — the interval's lower bound is zero, which is worth noting. The 84% pre-Omicron figure is from SIREN, a study of UK healthcare workers, who are neither demographically nor occupationally typical. Neither measured the lineages circulating now.

What is not known: how many times the average person has now been infected; whether risk from a fourth or fifth infection differs from a second; whether the accumulating-risk finding holds in a younger, healthier, vaccinated population; and what the reinfection interval looks like against the current XFG-descended lineages, since no surveillance system now tracks reinfection at population scale. CDC's 90-day surveillance convention is an administrative definition, not a biological one.

What survives all those caveats is modest and worth acting on: repeated infection is not risk-free, and the interventions that reduce it are the same ones that reduce first infection. For how that risk compares with other viruses, see our COVID-19 Risk Perspective and the hub's Virus Risk Perspective.